BPC 157 500mcg (60 Capsules)

BPC-157 Overview

BPC-157 is a Penta decapeptide (15 amino acids in length) derivative of the much larger, naturally occurring protein known as body protection compound or BPC. The original BPC peptide was isolated from human stomach contents where it is thought to play an important role in maintaining the integrity of the stomach wall against the erosive effects of stomach acid. Research on the protein revealed that the majority of its tissue-healing effects are contained within a small 15-amino-acid section that is now referred to as BPC-157. This smaller fragment is easier to produce synthetically and has become of interest in research settings.

BPC-157 has garnered a great deal of research setting because its healing abilities extend well beyond the lining of the stomach. Studies in animal models indicates that BP-157 can enhanced blood vessel formation (angiogenesis), promote wound healing, stimulate collagen synthesis, modulate the inflammatory response, and protect against oxidative stress. The peptide has shown benefits in animal models of inflammatory bowel disease, GI ulcers, musculoskeletal injury, heart damage, eye injury, and even neurological injury.

BPC-157 can be administered via SubQ admin or orally for research with lab animals. The oral bioavailability of BPC-157 is quite high. Though most research featuring oral administration of BPC-157 has focused on the peptide’s effects in the GI system, it can be absorbed and provide impact in other tissues. Interest in the oral benefits of BPC-157 has steadily increased given the therapeutic potential of the peptide and the rising incidences of both inflammatory bowel disease and heart disease.

BPC-157: Research

BPC-157: Stability and Bioavailability

One of the major factors that interests researchers in BPC-157 is its stability in the GI tract. Most medications need to be contained in pills or coated in various ways to allow them to survive the harsh environment of the stomach. This is not the case with BPC-157. While the peptide can be placed in capsules for easy research administration, such precautions are not necessary because the peptide is exceptionally stable in the GI tract. As a result of this stability, BPC-157 can be administered in a variety of ways including dissolving it in water or mixing it with food. This flexibility makes BPC-157 easy to work with in animal models.

BPC-157: Muscle and Tendon Healing

One of the earliest studies on BPC-157 looked at tendon and ligament healing in rat models. Tendons and ligaments, especially ligaments, are notoriously slow to heal due to their poor blood supply and relative lack of stem cells. Tendons and ligaments not only heal slowly as a result of these factors, they often heal in a manner that leaves them weaker than they were prior to injury. Low stem cell activity and limited blood supply both lead to decreased levels of remodeling following initial injury repair. Remodeling in wound healing is necessary to provide structural integrity and to align maximum tissue strength with highest stress loads. Limitations in this step mean weaker tissue strength and higher levels of scarring. When BPC-157 is administered to rats following experimental tendon injury, they not only show faster rates of initial healing, but also display higher levels of remodeling and subsequent improvements in tendon strength as a result[1]. These findings have led to high levels of interest in the role that BPC-157 might play in promoting tendon and ligament injury[2].

What has been especially interesting about animal trials of BPC-157 in muscle and tendon injury is the improved functional outcomes that have been observed. Researchers have seen improved clinical outcomes in rats administered BPC-157. These improved outcomes include factors like increased muscle motor function, decreased levels of joint contracture, and better preservation of walking patterns when compared to controls. These findings appear to directly correlate with the ability of BPC-157 to increase tendon outgrowth and cell survival, which leads to improvements in the microscopic structure of tendons and ligaments that improves functional outcomes[3]. In other words, the ability of BPC-157 to promote tissue remodeling following healing directly translates into measurable improvements in function.

BPC-157: Heart Muscle

Heart muscle is fundamentally different from skeletal muscle in several ways, but the wound healing processes share similarities. Researchers have therefore explored whether the benefits of BPC-157 can be extended to the heart. Studies in mice reveal that BPC 157 therapy has a complex effect on heart function. This peptide has been observed to effectively counteract chronic heart failure, normalize elevated endothelin levels, and reduce the long-term effects that occur following myocardial infarction. BPC-157 facilitates recovery by activating collateral pathways to compensate for vascular failure and has demonstrated both preventative and therapeutic effects. Notably, in models of lithium-induced heart muscle weakness, BPC 157 therapy led to a swift recovery of cardiac function alongside the alleviation of muscle weakness.
BPC-157 also appears to be effective against the early stages of multiorgan failure that occur due to heart attack and thus may offer insight into early recovery intervention as multiorgan failure following heart attack leads to a range of severe issues including hypertension, brain swelling, and widespread thrombosis (clot formation). Furthermore, BPC 157 has proven effective in countering various types of arrhythmias in animal models. This includes arrhythmias caused by digitalis overdose, hyperkalemia, hypokalemia, succinylcholine, bupivacaine, lidocaine, neuroleptics, and severe intoxication. It has also shown potential in addressing prolonged QTc intervals and other arrhythmias associated with pulmonary hypertension[5]. These findings all indicate that BPC-157 has a host of beneficial effects in the heart and may be useful not just in the treatment of acute cardiac issues, but in the prevention of cardiac maladies as well.

BPC-157: Wound Healing

BPC 157 is able to speed wound healing because it helps to restore blood flow to damaged tissues. Research shows that BPC 157 also increases the rate of vascular running, which refers to blood vessels growing toward an area of injury[6]. Beyond promoting blood vessel growth, BPC-157 enhances fibroblast activity. Fibroblasts play a crucial role in the repair process, as noted above, by synthesizing extracellular matrix (ECM) proteins, which form the structural framework for tissue repair. By increasing the migration and proliferation of fibroblasts to the site of injury, BPC 157 accelerates the initial phases of wound healing. This helps to quickly establish a scaffold of ECM, which is essential for tissue regeneration and repair. The peptide's effects on blood vessel growth further support this process by improving oxygen and nutrient supply to the damaged tissue, creating a more favorable environment for healing.[7].

BPC 157 is so effective in improving rates of wound repair that it has been investigated in fistula healing. Like tendons, fistulas are notoriously difficult to treat. The average fistula takes more than two and a half years to heal, even with everything that modern medicine has to throw at wound repair. With BPC 157, rates of healing in animal models are reduced to less than a month[8].

BPC-157: Central Nervous System

While much of the research around BPC-157 has focused on its benefits in the GI tract and musculoskeletal system, the connection between the gut and brain has led researchers to look at how BPC-157 may play a role in the central nervous system.

In rat models of stroke induced by blockage of the carotid arteries, BPC-157 was able to reduce damage to neurons. This, in turn, was manifest as improvements in memory, locomotion, and coordination as compared to control animals. In other words, BPC-157 appears to counteract the negative outcomes associated with reduced blood and oxygen supply to the brain. This benefit appears to be mediated, at least in part, by an upregulation in the nitric oxide system[9]. This system, in particular, is sensitive to levels of L-arginine in the body and helps to improve blood supply by dilating arteries[10].

BPC-157: Eye Health

The eyes are often, and accurately, considered to be part of the central nervous system. That said, they are also a unique element of anatomy that deserve their own mention, in part because there are diseases that are unique to the eyes that affect no other part of the body. Given the ability of BPC-157 to act in the central nervous system, it should come as no surprise that it has shown action in the eyes as well. In particular, BPC-157 has been shown to reverse glaucoma in rats, helping to restore intraocular pressure, recover pupil function, and maintain the health and integrity of the retina[11]. This is no small matter as glaucoma affects more than 64 million people world-wide and is the second leading cause of blindness in the United States.

Rats treated with BPC 157 display normal pupil diameter, well-preserved ganglion cells and optic nerve structure, as well as a healthy fundus. The retinal and choroidal blood vessels, as well as the optic nerve, appeared normal. Key symptoms, such as elevated intraocular pressure, dilated pupils, degeneration of retinal ganglion cells, excavation of the optic nerve head, thinning of the optic nerve, severe irregularities in retinal vessels, faint choroidal vessels, and significant atrophy of the optic nerve disc were all effectively reversed[11].

The mechanism by which BPC-157 works in the eyes appears to differ from other treatment modalities that came before it. This is important because it not only offers a therapeutic option in the setting where conventional therapy has failed, it also opens up avenues for future research and furthers our understanding of the glaucoma disease process. It appears that BPC-157 actually alleviates that occlusive process that leads to glaucoma in the first place. Thus, there is some sense that BPC-157 may be treating the underlying cause of glaucoma. If this turns out to be true, then it will shed new light on a very old disease and may even improve our understanding of how the eyes work at a fundamental level[11].

BPC-157: Gastrointestinal Healing

The natural place to research the function of BPC-157 is in the GI tract; after all, the peptide originates in the stomach. Interestingly, research in muscle and tendon healing may have provided insight into the role of BPC-157 in the GI tract and its ability to overcome tissue injury. Ulceration has been used as model for exploring the way in which BPC-157 promotes healing in the GI tract.

The development of ulcers is actually a poorly understood process. In fact, it wasn’t until about two decades ago that it was understood that bacteria (are responsible for many ulcers and that a combination of antibiotics and bismuth subsalicylate is curative in this particular setting. Therefore, it should come as no surprise that the roles of VEGF and EGF (endothelial growth factor) were not understood well in the setting of the GI tract. BPC-157 has helped to reveal that angiogenesis is a critically important component of healing in the GI tract. The ability of BPC-157 to not only stimulate the growth of new blood vessels by modulating levels of VEGF and EGF, but to improve the resilience of existing blood vessels, is proving to be a potent factor in healing in rat models of GI injury[12]. Never before has it been understood that vascular health in the GI tract is such a critical component of the healing process.

BPC-157: Summary

BPC-157 is synthetic derivative of a natural peptide isolated from the human GI tract. It has high bioavailability when administered orally or subcutaneously. It is resistant to stomach acid and, as such, can be administered in water or in food. Research in animal models, primarily rats, has shown benefits in heart disease, tendon injury, ligament injury, eye disease, the central nervous system, and inflammatory bowel disease. BPC-157 is helping to further our understanding of the workings of multiple organ systems and has opened up new research avenues into both the treatment and prevention of disease.

Storage Instructions:

All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping 3-4 months reconstituted (mixed with bacteriostatic water) to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days.

Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you're ready to reconstitute it with bacteriostatic water.

Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4C (39F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.

However, for longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80C (-112F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide’s stability.

‍